Compare AbbVie Inc (ABBV) vs SYSCO Corporation (SYY) Price & Performance

AbbVie IncTrade

SYSCO CorporationTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs SYSCO Corporation — how do they compare? AbbVie Inc trades at $247.79 (market cap $441.94B), while SYSCO Corporation trades at $83.7 (market cap $40.32B). The key difference: AbbVie Inc is far larger — about 11× SYSCO Corporation's market cap, and AbbVie Inc pays the higher dividend (2.77%). Which is the better fit depends on your goals.

	ABBV	SYY
Market Cap	$441.94B	$40.32B
Sector	Health	Consumer Staples
52-Week High	$263.58	$91.16
52-Week Low	$197.38	$69.30
Enterprise Value	$506.19B	$53.50B
Dividend Yield	2.77%	2.61%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.

Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.

SYSCO Corporation

SYY trades at $83.87, down 0.5% for the day, with a neutral technical signal and bullish moving averages. The company reported Q4 2026 EPS of $1.53, beating estimates, and revenue of $81.37B in 2025, with steady growth. Analyst consensus is a Buy with a $88.25 price target, and recent news highlights strong quarterly results and efficiency initiatives.

Outlook is positive due to earnings beats and growth initiatives, but risks include margin pressure and debt levels. The stock offers value with a P/E of 23.02 and P/S of 0.48, supported by institutional optimism, though macroeconomic uncertainty remains a concern.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

ABBV

Fidelity Dividend ETF's payout is safe but not ideal for steady income due to variable quarterly dividends.24/7 Wall Street · 1 day agoNeutral Two Dividend Aristocrats outperformed the market while two lagged; three new picks show promising dividend growth.24/7 Wall Street · 2 days agoNeutral Healthcare sector leads S&P 500 gains over 3 months with key pharma stocks showing strong innovation and income potential.24/7 Wall Street · 2 days agoBullish View details →

SYY

View details →

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

About SYSCO Corporation

Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.